Citations to this article
Citation Information: JCI Insight. 2017;2(13):e92264. https://doi.org/10.1172/jci.insight.92264.
Abstract
Nonalcoholic fatty liver disease prevalence is soaring with the obesity pandemic, but the pathogenic mechanisms leading to the progression toward active nonalcoholic steatohepatitis (NASH) and fibrosis, major causes of liver-related death, are poorly defined. To identify key components during the progression toward NASH and fibrosis, we investigated the liver transcriptome in a human cohort of NASH patients. The transition from histologically proven fatty liver to NASH and fibrosis was characterized by gene expression patterns that successively reflected altered functions in metabolism, inflammation, and epithelial-mesenchymal transition. A meta-analysis combining our and public human transcriptomic datasets with murine models of NASH and fibrosis defined a molecular signature characterizing NASH and fibrosis and evidencing abnormal inflammation and extracellular matrix (ECM) homeostasis. Dermatopontin expression was found increased in fibrosis, and reversal of fibrosis after gastric bypass correlated with decreased dermatopontin expression. Functional studies in mice identified an active role for dermatopontin in collagen deposition and fibrosis. PPARα activation lowered dermatopontin expression through a transrepressive mechanism affecting the Klf6/TGFβ1 pathway. Liver fibrotic histological damages are thus characterized by the deregulated expression of a restricted set of inflammation- and ECM-related genes. Among them, dermatopontin may be a valuable target to reverse the hepatic fibrotic process.
Authors
Philippe Lefebvre, Fanny Lalloyer, Eric Baugé, Michal Pawlak, Céline Gheeraert, Hélène Dehondt, Jonathan Vanhoutte, Eloise Woitrain, Nathalie Hennuyer, Claire Mazuy, Marie Bobowski-Gérard, Francesco Paolo Zummo, Bruno Derudas, Ann Driessen, Guy Hubens, Luisa Vonghia, Wilhelmus J. Kwanten, Peter Michielsen, Thomas Vanwolleghem, Jérôme Eeckhoute, An Verrijken, Luc Van Gaal, Sven Francque, Bart Staels
Total citations by year
Citations to this article in year 2022 (16)
| Title and authors | Publication | Year |
|---|---|---|
|
Serum amyloid A1 exacerbates hepatic steatosis via TLR4-mediated NF-κB signaling pathway
B Jiang, D Wang, Y Hu, W Li, F Liu, X Zhu, X Li, H Zhang, H Bai, Q Yang, X Yang, J Ben, Q Chen |
Molecular Metabolism | 2022 |
|
Expression of Fibrosis-Related Genes in Liver and Kidney Fibrosis in Comparison to Inflammatory Bowel Diseases
M Jerala, N Hauptman, N Kojc, N Zidar |
Cells | 2022 |
|
Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery
J Boeckmans, A Gatzios, A Heymans, M Rombaut, V Rogiers, J Kock, T Vanhaecke, R Rodrigues |
Cells | 2022 |
|
Deep proteomic profiling unveils arylsulfatase A as a non-alcoholic steatohepatitis inducible hepatokine and regulator of glycemic control
M Montgomery, J Bayliss, S Nie, W Nardo, S Keenan, P Miotto, H Karimkhanloo, C Huang, R Schittenhelm, A Don, A Ryan, N Williamson, G Ooi, W Brown, P Burton, B Parker, M Watt |
Nature Communications | 2022 |
|
Adaptation of Oxidative Phosphorylation Machinery Compensates for Hepatic Lipotoxicity in Early Stages of MAFLD
Fahlbusch P, Nikolic A, Hartwig S, Jacob S, Kettel U, Köllmer C, Al-Hasani H, Lehr S, Müller-Wieland D, Knebel B, Kotzka J |
International journal of molecular sciences | 2022 |
|
Molecular signatures of long-term hepatocellular carcinoma risk in non-alcoholic fatty liver disease
Fujiwara N, Kubota N, Crouchet E, Koneru B, Marquez CA, Jajoriya AK, Panda G, Qian T, Zhu S, Goossens N, Wang X, Liang S, Zhong Z, Lewis S, Taouli B, Schwartz ME, Fiel MI, Singal AG, Marrero JA, Fobar AJ, Parikh ND, Raman I, Li QZ, Taguri M, Ono A, Aikata H, Nakahara T, Nakagawa H, Matsushita Y, Tateishi R, Koike K, Kobayashi M, Higashi T, Nakagawa S, Yamashita YI, Beppu T, Baba H, Kumada H, Chayama K, Baumert TF, Hoshida Y |
Science Translational Medicine | 2022 |
|
Systematic Analysis of Long Non-Coding RNA Genes in Nonalcoholic Fatty Liver Disease
Ilieva M, Dao J, Miller HE, Madsen JH, Bishop AJ, Kauppinen S, Uchida S |
Non-Coding RNA | 2022 |
|
Dermatopontin Influences the Development of Obesity-Associated Colon Cancer by Changes in the Expression of Extracellular Matrix Proteins
Catalán V, Domench P, Gómez-Ambrosi J, Ramírez B, Becerril S, Mentxaka A, Rodríguez A, Valentí V, Moncada R, Baixauli J, Silva C, Escalada J, Frühbeck G |
International journal of molecular sciences | 2022 |
|
Differences of core genes in liver fibrosis and hepatocellular carcinoma: Evidence from integrated bioinformatics and immunohistochemical analysis
Li Y, Yuan SL, Yin JY, Yang K, Zhou XG, Xie W, Wang Q |
World journal of gastrointestinal oncology | 2022 |
|
CD4+ T cell activation and inflammation in NASH-related fibrosis
Zhou Y, Zhang H, Yao Y, Zhang X, Guan Y, Zheng F |
Frontiers in immunology | 2022 |
|
Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease
Sen P, Govaere O, Sinioja T, McGlinchey A, Geng D, Ratziu V, Bugianesi E, Schattenberg JM, Vidal-Puig A, Allison M, Cockell S, Daly AK, Hyötyläinen T, Anstee QM, Orešič M |
iScience | 2022 |
|
Functional genomics uncovers the transcription factor BNC2 as required for myofibroblastic activation in fibrosis.
Bobowski-Gerard M, Boulet C, Zummo FP, Dubois-Chevalier J, Gheeraert C, Bou Saleh M, Strub JM, Farce A, Ploton M, Guille L, Vandel J, Bongiovanni A, Very N, Woitrain E, Deprince A, Lalloyer F, Bauge E, Ferri L, Ntandja-Wandji LC, Cotte AK, Grangette C, Vallez E, Cianférani S, Raverdy V, Caiazzo R, Gnemmi V, Leteurtre E, Pourcet B, Paumelle R, Ravnskjaer K, Lassailly G, Haas JT, Mathurin P, Pattou F, Dubuquoy L, Staels B, Lefebvre P, Eeckhoute J |
Nature Communications | 2022 |
|
Folic acid depletion as well as oversupplementation helps in the progression of hepatocarcinogenesis in HepG2 cells
Sharma R, Ali T, Kaur J |
Scientific Reports | 2022 |
|
Intrahepatic paracrine signaling by CLCF1 ameliorates diet-induced NASH in mice
Liu T, Wang Q, Zhou L, Zhang P, Mi L, Qiu X, Chen Z, Kuang H, Li S, Lin JD |
Hepatology | 2022 |
|
Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism
Deprince A, Hennuyer N, Kooijman S, Pronk AC, Baugé E, Lienard V, Verrijken A, Dirinck E, Vonghia L, Woitrain E, Kloosterhuis NJ, Marez E, Jacquemain P, Wolters JC, Lalloyer F, Eberlé D, Quemener S, Vallez E, Tailleux A, Kouach M, Goossens J, Raverdy V, Derudas B, Kuivenhoven JA, Croyal M, van de Sluis B, Francque S, Pattou F, Rensen PC, Staels B, Haas JT |
Hepatology | 2022 |
|
Reprogramming of Hepatic Metabolism and Liver Microenvironment in Nonalcoholic Steatohepatitis
Rui L, Lin JD |
Annual Review of Nutrition | 2022 |
